Woodline Partners LP Immunovant, Inc. Transaction History

Woodline Partners LP

$17.6 Billion
Q2 2025

A detailed history of Woodline Partners LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 1,498,725 shares of IMVT stock, worth $41.2 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

1,498,725

Previous 1,497,869 0.06%

Holding current value

$41.2 Million

Previous $41.2 Million 0.06%

% of portfolio

0.23%

Previous 0.29%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	N/A	856 Added 0.06%	1,498,725 $41.2 Million
Q1 2025 May 15, 2025	BUY	N/A	855,143 Added 133.05%	1,497,869 $41.2 Million
Q4 2024 Feb 14, 2025	SELL	N/A	-772,251 Reduced 54.58%	642,726 $17.7 Million
Q3 2024 Nov 14, 2024	SELL	$27.51 - $27.51 $11.2 Million - $11.2 Million	-408,438 Reduced 22.4%	1,414,977 $38.9 Million
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $13.4 Million - $16.9 Million	533,911 Added 41.4%	1,823,415 $48.1 Million
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $16.3 Million - $23.6 Million	539,238 Added 71.87%	1,289,504 $41.7 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $6.69 Million - $9.45 Million	-213,817 Reduced 22.18%	750,266 $31.6 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $6.1 Million - $13.1 Million	328,992 Added 51.8%	964,083 $37 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $7.06 Million - $11.8 Million	497,499 Added 361.58%	635,091 $12 Million
Q1 2023 May 15, 2023	SELL	$15.27 - $19.72 $10.4 Million - $13.4 Million	-679,367 Reduced 83.16%	137,592 $2.13 Million
Q4 2022 Feb 14, 2023	SELL	$6.59 - $17.75 $6.24 Million - $16.8 Million	-947,331 Reduced 53.69%	816,959 $14.5 Million
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $6.57 Million - $10.7 Million	1,672,190 Added 1815.62%	1,764,290 $9.85 Million
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.65 $311,298 - $520,365	92,100 New	92,100 $359,000
Q4 2021 Feb 14, 2022	SELL	$7.33 - $9.32 $1.77 Million - $2.25 Million	-241,599 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $24.6 Million - $39.9 Million	-3,508,976 Reduced 93.56%	241,599 $2.1 Million
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $26.8 Million - $48.1 Million	2,853,958 Added 318.3%	3,750,575 $39.6 Million
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $7.78 Million - $29.5 Million	594,714 Added 196.99%	896,617 $14.4 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $5.84 Million - $8.47 Million	160,733 Added 113.86%	301,903 $13.9 Million
Q3 2020 Nov 16, 2020	SELL	$22.61 - $38.9 $2.03 Million - $3.49 Million	-89,738 Reduced 38.86%	141,170 $4.97 Million
Q2 2020 Aug 14, 2020	SELL	$13.87 - $28.44 $1.31 Million - $2.68 Million	-94,275 Reduced 28.99%	230,908 $5.62 Million
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $440,103 - $901,791	52,644 Added 19.32%	325,183 $5.06 Million
Q4 2019 Feb 14, 2020	BUY	$10.02 - $16.4 $2.73 Million - $4.47 Million	272,539 New	272,539 $4.32 Million

Others Institutions Holding IMVT

# of Institutions

195

Shares Held

78.7M

Call Options Held

428K

Put Options Held

396K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Immunovant, Inc. Transaction History